Topics Comments

 < Previous page    Next page > 
Cheung Kong VODone Limited Shenzhen International Holdings Limited Jiangxi Copper Company Limited REXLot Holdings Limited China Overseas Land & Investment Limited Chong Hing Bank Limited Agricultural Bank of China Limited Chow Tai Fook Jewellery Group Limited Capital VC Limited iShares A50 Standard Chartered Bank of Communications Bank of China China LotSynergy Holdings Limited agribank Agri Airlines Appl AUD Auto A Shares Brokers CAD fertilizer producers China Lottery Supermarket China Banks Communication Consumer China Econ Electricity China Finance China IT Petro Real Est China Resource Steel coal Commodity Beauty Drugs Enviro EURO Lang Simon Ting WongSir Andy Xie Expo Gambling Garment gas GBD Gold Gold Jew Gold mine Harbour Highways HK Apparel REITs Rentals HK Banks ETF HK Housing Market Real Est HK HK Stock iBond Infra Insure IPO jewel Mach Build Mat New Energy NZD Oil Paper Rare Earths Real Estate Market Food RMB Rising RMB RMB Bonds Shipbuilding Shipping Sports Stock Trend Taiwan Dollar (TWD) Textile Top 500 USD US Econ Util Water Yang Liu's 10 Stocks YEN Diary media Central Bank Monetary Policy Education Construction Emerging markets Nuclear power BillGross Cement HK retail logistics Swiss franc Social Security Fund Law Ka-Chung capital flow Financial and political policy Railway film Korean Won Roubini Faber Mobius
Topics Last reply time Nickname Content
CSPC Pharmaceutical Group Limited 2019-12-13T14:47 財經茄呢啡 醫藥股繼續反彈,石藥集團周四升逾2%,高位升穿17.7元。向上觀望重上18元的機會,並留意17元能否得到支撐。睇好可考慮石藥購11412,行使價19.82元,20年2月到期。或石藥牛63177,收回價15.18元,行使價14.48元,20年7月到期。相反看空可留意石藥沽11722,行使價15.88元,20年4月到期。或石藥熊63178,收回價19.28元,行使價19.98元,20年7月到期。
CSPC Pharmaceutical Group Limited 2019-12-13T14:47 財經茄呢啡 瑞信明年較睇好中資藍籌,尤其是公用事業股。當中包括配合國家基建發展的中國中鐵,預料潛在升幅達88.8%,昨天收市報4.65元;另外推薦中國海外、中海油及中國燃氣。該行又睇好中國平安,相信其產品多樣化將有利可持續增加,昨天收市升0.5%報91.3元,預料潛在升幅19.4%;而石藥集團創新藥物銷售有望增加,潛在升幅39.5%,昨天收市報17.86。
CSPC Pharmaceutical Group Limited 2019-12-13T14:47 財經茄呢啡 12月9日,河北省醫藥行業協會三屆三次理事(擴大)會在石家莊召開,會上,決定授予石藥控股集團有限公司「2018年度河北省醫藥工業十強企業」「2018年度河北省醫藥利稅大戶」稱號,授予石藥集團河北中誠醫藥有限公司「2018年度河北省藥品流通行業優勢企業」稱號,授予石藥集團歐意藥業有限公司科研項目「阿奇霉素原料和制劑的技術開發及國際化」「2017年度河北省醫藥行業科學技術進步」一等獎榮譽。
CSPC Pharmaceutical Group Limited 2019-12-06T14:55 財經茄呢啡 醫藥股獲投資者追捧,中國生物制藥升2.2%,中午收市報10.34元,石藥集團升0.5%,中午收市報17.54元,藥明生物升0.3%,中午收市報87.35元。
CSPC Pharmaceutical Group Limited 2019-12-06T14:55 財經茄呢啡 恩必普(化學名:丁苯酞)是石藥集團新藥研發成果的代表之一,是我國第三個具有自主知識產權的國家一類新藥,也是腦卒中治療領域的全球領先藥物,上市以來為1000多萬名卒中患者治愈或減輕了疾病困擾。與此同一時間,石藥集團還有玄寧、歐來寧、津優力、多美素、諾利寧、克艾力等多個新藥產品。這些新藥的成功上市和快速成長,有幫帶動石藥集團產品結構實現了從普藥經營為主到創新藥經營為主的華麗轉身。
CSPC Pharmaceutical Group Limited 2019-12-06T14:55 財經茄呢啡 輝立公布報告稱,石藥集團經過二十余年發展,由國內最重要的原料藥供應商成功轉型為以創新品牌藥為主導的高技術企業,石藥集團的創新藥板塊重要瞄准心腦血管和抗腫瘤兩大領域,公司營銷效率高,研發投入大,人均產出和研發實力領先。
CSPC Pharmaceutical Group Limited 2019-11-29T15:15 財經茄呢啡 周五大部分內地醫藥股大跌,當中兩只藍籌醫藥股石藥集團及中國生物制藥分別大跌10%及4%。信達生物跌4.7%,上海醫藥則微升0.4%。
CSPC Pharmaceutical Group Limited 2019-11-29T15:15 財經茄呢啡 中國新版醫保目錄談判結果出爐,新增進入藥品價錢平均回軟60.7%,醫藥股在中港兩地齊跌,中國生物制藥與石藥集團分別回軟4.33%和11.25%,成為跌幅前兩大的恆指成分股。
CSPC Pharmaceutical Group Limited 2019-11-29T15:15 財經茄呢啡 醫藥股近期出現調整,其中石藥集團今早跌勢明顯,黃相信,重要由於內地最新發布新版醫保藥品名單,當中有70種談判藥品價錢回軟六成以上,令市場擔心或令藥企盈利收窄,加上內地亦正研究第三輪帶量采購的方向,藥企面對政策風險,盈利增加空間或放緩。而兩大藍籌藥股石藥及中生制藥早前累升已多,技術上已出現「頂背馳」,RSI動力減弱,在政策逆風下,醫藥股或有進一步調整,現時買進風險頗大。
CSPC Pharmaceutical Group Limited 2019-11-29T15:15 財經茄呢啡 醫藥股被賣出,石藥集團半日收報17.52元,跌11.2%;中國生物制藥半日收報10.16元,跌4.33%;康哲醫藥半日收報10.72元,跌8%;四環醫業半日收報0.89元,回軟2.1%。
 < Previous page    Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.